Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Creative Medical Technology Holdings Inc (CELZ)

Creative Medical Technology Holdings Inc (CELZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,346
  • Shares Outstanding, K 1,330
  • Annual Sales, $ 10 K
  • Annual Income, $ -5,290 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 2.01
  • Price/Sales 611.75
  • Price/Cash Flow N/A
  • Price/Book 0.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.85
  • Number of Estimates 1
  • High Estimate -0.85
  • Low Estimate -0.85
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.78 +26.26%
on 10/08/24
5.58 -37.10%
on 10/16/24
+0.51 (+17.00%)
since 10/04/24
3-Month
2.65 +32.45%
on 09/20/24
5.58 -37.10%
on 10/16/24
+0.25 (+7.67%)
since 08/02/24
52-Week
2.65 +32.45%
on 09/20/24
10.28 -65.86%
on 03/07/24
-1.14 (-24.52%)
since 11/03/23

Most Recent Stories

More News
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

CELZ : 3.51 (-12.69%)
Creative Medical Technology Skyrockets on Word of New Diabetes Medication

Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) shares nearly doubled in price Thursday. The ...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Announces $2 Million Share Repurchase Program

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Holdings Provides Corporate Update

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Holdings Announces Reverse Stock Split

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially...

CELZ : 3.51 (-12.69%)
SYNH : 42.98 (+0.02%)
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially...

CELZ : 3.51 (-12.69%)
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of...

CELZ : 3.51 (-12.69%)

Business Summary

Creative Medical Technology Holdings Inc. is a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics. Creative Medical Technology Holdings Inc. is based in PHOENIX.

See More

Key Turning Points

3rd Resistance Point 4.58
2nd Resistance Point 4.35
1st Resistance Point 3.93
Last Price 3.51
1st Support Level 3.28
2nd Support Level 3.05
3rd Support Level 2.63

See More

52-Week High 10.28
Fibonacci 61.8% 7.37
Fibonacci 50% 6.47
Fibonacci 38.2% 5.57
Last Price 3.51
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar